Journey Medical Corp expected to post a loss of 8 cents a share - Earnings Preview

Journey Medical

18/03/2024 03:03

* Journey Medical Corp  DERM.OQ   DERM.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 21
for the period ending December 31 2023
    * The Scottsdale Arizona-based  company is expected to
report a
5.7% decrease in revenue to $15.061 million from $15.97 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Journey Medical Corp is
for a
loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Journey
Medical
Corp is $8.00​, above​ its last closing price of $3.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.11       -0.15      0.80      Beat    616.1
 Jun. 30 2023  -0.35       -0.33      -0.29     Beat    13.4
 Mar. 31 2023  -0.45       -0.45      -0.57     Missed  -27.6​
 Dec. 31 2022              -0.47      -0.60     Missed  -28.6
 ​​Sep.        -0.50       -0.40      -0.57     Missed  -43.7
 30 2022                                                
 Jun. 30 2022  -0.26       -0.26      -0.43     Missed  -67.5​
 Mar. 31 2022  -0.31       -0.31      -0.08     Beat    74.2
 Dec. 31 2021  -0.45       -0.41      -1.64     Missed  -296.8
 This summary was machine generated March 18 at 03:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)